key: cord-0931963-ij3mgm7p
authors: Venugopal, Usha; Jilani, Nargis; Rabah, Sami; Shariff, Masood A.; Jawed, Muzamil; Batres, Astrid Mendez; Abubacker, Muhamed; Menon, Sharika; Pillai, Anjana; Shabarek, Nehad; Kasubhai, Moiz; Dimitrov, Vihren; Menon, Vidya
title: SARS-CoV-2 Seroprevalence Among Health Care Workers in a New York City Hospital: A Cross-Sectional Analysis During the COVID-19 Pandemic
date: 2020-10-16
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.10.036
sha: 6420ef190193c2abe86e8061d789dd383854c1c2
doc_id: 931963
cord_uid: ij3mgm7p

Background New York City (NYC) has endured the greatest burden of COVID-19 infections in the US. Health inequities in South Bronx predisposed this community to a greater number of infections cases, hospitalisations and mortality. Health Care Workers (HCWs) are at high-risk of exposure to the infection. This study aims to assess seroprevalence and associated characteristics of consenting HCWs from a NYC public hospital. Methods Cross sectional study including serum samples for qualitative SARS-CoV-2 antibody testing with nasopharyngeal swabs for SARS-CoV-2 PCR and completion of an online survey capturing demographics, COVID-19 symptoms during the preceding months on duty, details of healthcare and community exposure, and travel history were collected from consenting participants in May 2020. Participants’ risk of exposure to COVID-19 infection in hospital and in the community was defined based on CDC guidelines. Travel history to high-risk areas was also considered an additional risk. The Odds Ratio with bivariable and multivariable logistic regression was used to assess characteristics associated with seroprevalence. Results A total of 500 HCW were tested, 137 (27%) tested positive for SARS-CoV-2 antibody. Symptomatic participants had a 75% rate of seroconversion compared to those without symptoms. Subjects with anosmia and ageusia had increased odds of seroconversion in comparison to those without these symptoms. Community exposure was 34% among those who had positive antibodies. Conclusion Seroprevalence among HCWs was high compared to the community at the epicenter of the pandemic. Further studies to evaluate sustained adaptive immunity in this high-risk group will guide our response to a future surge.

New York City (NYC) has endured the greatest burden of COVID-19 infections in the US.

Health inequities in South Bronx predisposed this community to a greater number of infections cases, hospitalisations and mortality. Health Care Workers (HCWs) are at high-risk of exposure to the infection. This study aims to assess seroprevalence and associated characteristics of consenting HCWs from a NYC public hospital.

Cross sectional study including serum samples for qualitative SARS-CoV-2 antibody testing with nasopharyngeal swabs for SARS-CoV-2 PCR and completion of an online survey capturing demographics, COVID-19 symptoms during the preceding months on duty, details of healthcare and community exposure, and travel history were collected from consenting participants in May 2020. Participants' risk of exposure to COVID-19 infection in hospital and in the community was defined based on CDC guidelines. Travel history to high-risk areas was also considered an additional risk. The Odds Ratio with bivariable and multivariable logistic regression was used to assess characteristics associated with seroprevalence.

A total of 500 HCW were tested, 137 (27%) tested positive for SARS-CoV-2 antibody.

Symptomatic participants had a 75% (98/130) rate of seroconversion compared to those without symptoms. Subjects with anosmia and ageusia had increased odds of seroconversion in comparison to those without these symptoms. Community exposure was 34% (44/130) among those who had positive antibodies.

Seroprevalence among HCWs was high compared to the community at the epicenter of the pandemic. Further studies to evaluate sustained adaptive immunity in this high-risk group will guide our response to a future surge. City (1). Black and Hispanic residents in the city had higher rates of hospitalization and death due to COVID-19 (2) . Older age and higher number of comorbidities like chronic kidney disease, cancer, COPD, immune-compromised state, obesity, congestive heart failure, diabetes and others increase risk for adverse outcomes (3) . While most patients with SARS-CoV-2 infection have clinical presentation ranging from mild to severe respiratory illness, there is compelling evidence of asymptomatic and pre-symptomatic transmission of this infection creating a breakdown of public health strategies to control the infection (4).

Antibodies to the spike (S) protein are considered to be the primary target of neutralizing activity following SARS-CoV-2 infection, conferring protective immunity compared to the membrane (M), envelope (E), and nucleocapsid proteins (5) . While there is better understanding of the immunological response to SARS-CoV-2 infection, there is a lack of serological assays to specifically detect SARS-CoV-2 antibodies. There is data to suggest that in a high prevalence setting the commonly available commercial assays can miss SARS-CoV-2 antibodies, and the sensitivity of these assays are insufficient to detect the neutralizing capacity of seropositive individuals (6) . CDC reported that about 55% of SARS-CoV-2 PCR positive HCWs, reported exposure at work, with most of them being minimally symptomatic or asymptomatic (7) . Convenience sampling of 3000 people in NY State showed 13.9-14.9% of the population have COVID-19 antibodies (8) . A large cohort study of HCW in the greater NYC area showed a seroprevalence SARS-CoV-2 antibodies at 13.7% (9) . Seroprevalence study of a representative sample of HCW from Spain during the peak of the pandemic showed 9.3% had antibodies to SARS-CoV-2, while a similar hospital wide screening study from Belgium confirmed only 6.4% of the hospital staff had antibodies (10, 11) . We present the results of a cross-sectional study to assess seroprevalence of SARS-CoV-2 IgG antibody among HCWs at a heavily impacted community hospital during the COVID-19 pandemic in NYC.

The cohort included HCWs across all hospital services who worked at the level one trauma center in the South Bronx during the period from March 1 to May 1, 2020. The study received institutional review board approval (IRB # 20-009).

After informed consent was obtained, participants underwent qualitative serology testing 19 infection such as fever, cough, shortness of breath, anosmia, ageusia, myalgia, nausea and/or diarrhea in the preceding 8-10 weeks was also requested.

Risk of exposures in healthcare setting and community exposure were determined based on CDC guidelines (13) . Close contact for healthcare exposures is defined as being within approximately 6 feet of a person with COVID-19 for a prolonged period (such as caring for the patient, or sitting within 6 feet of the patient in a waiting area or room) or having unprotected direct contact with infectious secretions or excretions of the patient (e.g., being coughed on, touching used tissues with a bare hand). High-risk exposure is defined as HCW who have had prolonged close contact with patients with COVID-19 who were not wearing a facemask while the HCW nose and mouth were exposed to material potentially infectious with the virus causing COVID-19 or being present in the room for procedures that generate aerosols or during which respiratory secretions are likely to be poorly controlled (e.g., cardiopulmonary resuscitation, intubation, extubation, bronchoscopy, nebulizer therapy, sputum induction) on patients with COVID-19 when the HCP eyes, nose or mouth were not protected. Medium-risk exposure is defined as HCW who had prolonged close contact with patients with COVID-19 who were not wearing a facemask while the HCW nose and mouth were exposed to material potentially infectious with the virus causing COVID-19. Low-risk exposure includes brief interactions with patients with COVID-19 or prolonged close contact with patients who were wearing a facemask for source control while the HCP were wearing a facemask or a respirator with use of eye protection, in addition to a facemask or respirator would further lower the risk of exposure. Individuals outside of healthcare setting with close contact (<6 feet) for ≥15 minute to a person with COVID-19 who had symptoms (in the period from 2 days before symptom onset clinically compatible illness) or person who has tested positive for COVID-19 (laboratory confirmed), but were asymptomatic in the 2 days J o u r n a l P r e -p r o o f prior to the date of specimen collection until they meet criteria for discontinuing home isolation has community exposure. High risk areas for domestic travel were identified as California and Washington State, while the international high-risk areas were China, South Korea, Iran, Italy, and Spain.

Descriptive statistics was used to summarize the baseline characteristics of the cohort and key study outcome variables. Categorical variables were compared by Chi-squared test and student t-test for continuous variables. Missing data were imputed with mean for continuous variables. Binomial logistic regression was used to calculate odds ratios and 95% CI for evaluating the association with seroprevalence of socio-demographic variables. Significant symptoms and exposure related variables observed to be associated with seropositivity in bivariate analysis (cut-off of p<0.15) were independently assessed by multivariable logistic regression for its association with seropositivity, adjusting for all significant variables as covariates. A p-value of <0.05 was considered significant. All statistical tests were performed using SPSS version 17 (IBM, USA)

Among the 659 participants screened for the study, 500 consented and underwent PCR and antibody testing, and 478 participants completed the survey. The participants who completed the survey were included in the evaluation and analysis of characteristics predisposing to seroprevalence. Overall study participants were female (69%), under the age of 40 (48%), Hispanic (28%), Asian and Caucasian (24%) racial/ethnic distribution, with 33% being physicians followed by nurses (30%). Hypertension, asthma/COPD and diabetes were the common comorbidities. Childhood BCG vaccination was reported by 43% of participants.

Most participants lived in NYC boroughs and used either public transport or walked to work.

In our study group 53% were asymptomatic. Symptomatic participants reported sore throat/sinusitis (67%), myalgia (57%) and fever (36%) with 39% having symptoms for up to two weeks. Most HCWs (85%) had a prior test for SARS-CoV-2 PCR, with 19% of those being positive. Among the HCWs involved in direct patient care 14% had high/moderate risk exposure. Community exposure due to household contact with COVID-19 was present in 18% of the participants.

In the overall cohort, the prevalence of SARS-CoV-2 IgG antibodies was 27% (137/500). Of the participants that completed the survey, 130 were positive for IgG antibodies. Ninety-eight (75%) of the 130 participants with positive antibodies had COVID-19 like symptoms in the preceding 10 weeks. Among the symptomatic participants 44% (98/225) were seropositive compared to 13% (32/253) without symptoms. p<0.001) (Fig. 1) . On multivariate analysis (Table 2) , HCWs who reported symptoms of fever, ageusia and anosmia were 7.4, 3.3 and 5.5 times respectively likely to be seropositive compared to those without the aforesaid symptoms. Participants with symptoms above 14 days were 4.3 times likely to be seropositive compared to those with symptoms less than 5 days. High and moderate risk of exposure was twice as likely to be associated with seropositivity compared to low risk.

Based on the results of viral PCR and antibody testing, 3 subgroups of the cohort were identified (Fig. 2) . Of the 130 participants who were antibody positive, 105 had a negative SARS-CoV-2 PCR during the study. In this subgroup, 60 subjects had prior PCR positivity, with 50 being symptomatic. Twenty two of the 25 subjects who were both PCR and antibody positive at the time of study, had prior PCR positivity with 18 reporting symptoms of COVID like illness. Among 348 participants who tested negative for viral PCR and anti SARS-CoV-2 antibody at the time of testing, 285 (82%) did not report any detectable viral RNA anytime in the past 3 months (study period) with predominantly low-risk healthcare exposure (255/347-73%). This sub-cohort were younger participants less than 40 year of age, without any major comorbidities and of these 98 (35%) reported sore throat/ sinusitis (62/98) and myalgia (46/98). Seven participants with prior positive PCR, including 4 who were symptomatic were seronegative at the time of study. Both groups had low-risk healthcare exposure.

We report the seroprevalence of SARS-CoV-2 in a cross-sectional sample of HCWs who worked at the frontlines in one of NYC's public hospitals. The 27% seroprevalence in our high-risk cohort is comparable to 24.4 % observed in a cross-sectional study of 554 HCWs from hospital in UK (14) . Recent data from a university hospital in US supports the considerably higher prevalence of COVID-19 infection among HCWs in comparison with non-HCWs (7.3% vs 0.4%) (15) . On a similar vein, a previous study done during the influenza A (H1N1) pandemic that occurred in 2009, where in a multicentre study to evaluate seroprevalence before and after the vaccination, showed that first-responders that interacted with 5 or more infected patients mounted a significantly higher seropositivity (16). infection was present in the NYC metropolitan area, prior to March 1 st (9, 10) . The seroprevalence in the representative sample was 19.3% in late April suggesting low community seroprevalence (10) . We believe the higher seroprevalence seen in our cohort, could be a combination of healthcare and community exposure as our hospital was the "epicenter of the epicenter" during the pandemic and most of the HCWs lived in and around NYC.

In our analysis, after adjustment for baseline characteristics, on multivariate regression analysis, we did not find any racial/ethnic predisposition to seropositivity among HCW. On the contrary, there has been published data favouring association of SARS-CoV-2 seropositivity in non-Hispanic blacks and Hispanics when compared to whites in the general population (17) (18) (19) (20) . The reasons for this disparity could be factors related to social determinants of health, increased comorbidities and higher likelihood of people from these communities to be essential workers, increasing their risk of exposure to the infection (21).

We observed a difference in seropositivity among prior symptomatic and asymptomatic HCWs (44% vs 13%), similar to a cross sectional study of HCWs from the UK (35.8% vs 17.1%) (14) . The persistence of PCR positivity in 22 of the 25 participants who were seropositive, seemed less likely to be infectious, though we do not have viral load estimation to corroborate. As has been shown in previous studies, ageusia and anosmia were highly associated (OR> 24) with seropositivity (22) . The lower seropositivity rates among asymptomatic participants suggests that developing the disease following the infection was important factor influencing presence of antibodies. Among the 43% (204/478) participants who had received BCG vaccination in childhood, 63 (31%) developed antibodies to SARS-

CoV-2 compared to 27% seropositivity in the entire cohort, the difference was however not significant.

Multiple studies on community prevalence and among HCW have shown a wide ranging of seropositivity for SARS-CoV-2 antibodies in the NYC area ranging from 6.9% to 27%, which is well below the estimated 67% needed to achieve herd immunity to SARS-CoV-2 (23) . Hence implementation of protocols and workflows to reduce exposure and transmission among HCWs must be implemented to protect the frontline HCWs during a second surge. group of subjects based on timing of the study, since IgM tests were not performed which could reflect more recent infections as compared to IgG. Fifth, we were able to receive only 478 survey among our tested 500 participants which could also contribute to bias. Finally, we did not determine dynamic antibody responses at this time, though we plan it for the future.

In conclusion, HCWs tested after the initial surge following the COVID-19 pandemic, have demonstrated a higher seroprevalence compared to the community in NYC. Symptomatic participants had a higher rate of seropositivity compared to those without symptoms. It is likely that a combination of healthcare and community exposure contributed to the seroprevalence. While the present assessment, might not be a true indicator of immunity to the SARS-CoV-2 virus due to barriers in the testing method, timing of the testing etc., further studies are warranted to better understand our adaptive immune response.

None to report for any of the authors.

UV, VD and VM conceptualized and designed of the study, or acquisition of data, or analysis and interpretation of data, additionally drafting the article or revising it critically for important intellectual content. NJ, SR, MJ, MA, and SM worked on acquisition of data, its analysis and interpretation followed by drafting the article and tables and revising them. MAS and AMB were involved in patient recruitment and follow-through, acquisition of data, quality review and analysis with interpretation of results and drafting and revising the manuscript. AP, NS and MK were involved in interpretation of data and revising it critically for intellectual content. All authors approved the final version of the submission.

We are grateful to all the HCWs for their heroic efforts during the pandemic and to our study participants. We appreciate the continued support of the 

The study protocol was approved by the Institutional Review Board Committee (IRB# 20-009) on 5/1/2020. All patients provided written Informed Consent to participate in the study. 

Addressing Health Inequities in Care During COVID-19

Asymptomatic and presymptomatic transmission of SARS-CoV-2: A systematic review

Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity

Sensitivity of commercial Anti-SARS-CoV-2 serological assays in a high-prevalence setting

Center for Disease Control and Prevention, Characteristics Of Health Care Personnel with COVID-19 -United States

Amid Ongoing COVID-19 Pandemic, Governor Cuomo Announces Phase II Results J o u r n a l P r e -p r o o f of Antibody Testing Study Show 14

Prevalence of SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area

Seroconversion of a city: Longitudinal monitoring of SARS-CoV-2 seroprevalence in New York City

Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a

Food and Drug Administration, SARS-C0V-2 IgG Architect. Abbot Instruction Manual

Public Health Guidance for Community-Related Exposure

SARS-CoV-2 seroconversion in health care workers

Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers at the onset of the U.S. COVID-19 epidemic

Seroprevalence of Pandemic A(H1N1) pmd09 Virus Antibodies in Mexican Health Care Workers Before and After Vaccination

Estimated Community Seroprevalence of SARS-CoV-2 Antibodies -Two Georgia Counties

Characteristics Associated with Hospitalization Among Patients with COVID-19

Racial and workplace disparities in seroprevalence of SARS-CoV-2 in

Population Point Prevalence of SARS-CoV-2 Infection Based on a Statewide Random Sample -Indiana

Black workers face two of the most lethal preexisting conditions for coronavirus-racism and economic inequality

Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital

COVID-19 herd immunity: where are we?

Model for Taking Care of Patients with Early Childhood Caries during the SARS-Cov-2 Pandemic

Low Risk HCW defined as: Brief interactions with patients with COVID-19 or prolonged close contact with patients who were wearing a facemask for source control while the HCP were wearing a facemask or respirator. f: Community Exposure defined as: Individual had close contact (< 6 feet) for ≥15 minute to a person with COVID-19 who had symptoms or Person who has tested positive for COVID-19 but were asymptomatic. g: High Risk Domestic locations include: California and Washington state

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.